MUC5B突变携带者类风湿关节炎相关间质性肺病的终生风险
基于芬兰FinnGen队列研究,在6869例类风湿关节炎患者中评估MUC5B启动子变异rs35705950与间质性肺病终生风险的关系。MUC5B携带者80岁时间质性肺病终生风险为16.8%,非携带者为6.1%,风险差异从65岁开始显现,男性风险更高。
要点
- MUC5B变异携带者RA患者80岁时ILD终生风险为16.8%,非携带者为6.1%。
- RA患者中MUC5B变异与ILD风险增加相关,HR为2.27(95%CI 1.75-2.95)。
- 风险差异从65岁开始显现,男性风险更高。
核心结论
- MUC5B突变携带状态可用于类风湿关节炎相关间质性肺病的风险分层。
研究设计与样本
- FinnGen研究整合芬兰全国登记系统长达50年随访的流行病学队列与医院生物样本库遗传数据。
- 从芬兰国家出院、药物报销和死因登记中识别类风湿关节炎和间质性肺病患者。
主要发现
- 全数据集中MUC5B增加间质性肺病风险,HR为2.44(95%CI 2.22-2.68)。
- 6869例类风湿关节炎患者中247例(3.6%)发生间质性肺病,MUC5B的HR为2.27(95%CI 1.75-2.95)。
- 类风湿关节炎患者中MUC5B携带者间质性肺病终生风险为16.8%(95%CI 13.1%-20.2%),非携带者为6.1%(95%CI 5.0%-7.2%)。
- 风险差异从65岁开始显现,男性风险更高。
关键数值与推荐
- 类风湿关节炎患者80岁时间质性肺病终生风险:MUC5B携带者16.8%(95%CI 13.1%-20.2%),非携带者6.1%(95%CI 5.0%-7.2%)。
临床怎么用
- 对类风湿关节炎患者可考虑检测MUC5B rs35705950变异以辅助间质性肺病风险分层。
- MUC5B携带者尤其男性在65岁后应加强间质性肺病监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate lifetime risk of developing rheumatoid arthritis-associated interstitial lung disease (RA-ILD) with respect to the strongest known risk factor for pulmonary fibrosis, a MUC5B promoter variant. METHODS: FinnGen is a collection of epidemiological cohorts and hospital biobank samples, integrating genetic data with up to 50 years of follow-up within nationwide registries in Finland. Patients with RA and ILD were identified from the Finnish national hospital discharge, medication reimbursement and cause-of-death registries. We estimated lifetime risks of ILD by age 80 with respect to the common variant rs35705950, a MUC5B promoter variant. RESULTS: Out of 293 972 individuals, 1965 (0.7%) developed ILD by age 80. Among all individuals in the dataset, MUC5B increased the risk of ILD with a HR of 2.44 (95% CI: 2.22 to 2.68). Out of 6869 patients diagnosed with RA, 247 (3.6%) developed ILD. In patients with RA, MUC5B was a strong risk factor of ILD with a HR similar to the full dataset (HR: 2.27, 95% CI: 1.75 to 2.95). In patients with RA, lifetime risks of ILD were 16.8% (95% CI: 13.1% to 20.2%) for MUC5B carriers and 6.1% (95% CI: 5.0% to 7.2%) for MUC5B non-carriers. The difference between risks started to emerge at age 65, with a higher risk among men. CONCLUSION: Our findings provide estimates of lifetime risk of RA-ILD based on MUC5B mutation carrier status, demonstrating the potential of genomics for risk stratification of RA-ILD.
引用
- Palomäki A, Palotie A, Koskela J, et al. Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers. Ann Rheum Dis. 2021. PMID: 34344703. doi:10.1136/annrheumdis-2021-220698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。